Project Grant R21AR084116
Award Date
9/18/24
Completion Date
8/31/26
Dollars Obligated
$300K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $715,957 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Northwestern University to conduct research on the mechanisms underlying interferon-induced T peripheral helper (Tph) cell differentiation in systemic lupus erythematosus (SLE). The project, which runs from March 2025 to February 2030, will apply cutting-edge biochemical, epigenetic, and genetic approaches to...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $216,113 to New York University School of Medicine to conduct research on the mechanisms of hematological abnormalities in systemic autoimmunity. The research aims to characterize the impairment of hematopoietic stem cells (HSCs) in a mouse model of systemic lupus erythematosus...
This Project Grant award under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research program (CFDA 93.855) provides $558,045 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study the role of the protein phosphatase 2A (PP2A) enzyme in regulating T cell function and inflammation in systemic lupus erythematosus (SLE). The research aims to determine how PP2A controls enzymes involved in the glycolysis and pentose phosphate pathways,...
This $1,540,008 five-year federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance the understanding of skin inflammation and immune-stromal cell interactions in systemic lupus erythematosus (SLE). The Integrated Program for Cutaneous Immune-Stromal Interactions in SLE (IPCISS) will conduct interdisciplinary basic and translational research to: 1) fully define...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to understand the mechanisms linking cutaneous photosensitivity and systemic autoimmunity in systemic lupus erythematosus (SLE). The $788,508 award to The Hospital For Special Surgery Fund, Inc. will investigate how Langerhans cells regulate dermal lymphatic function and its...
This $2,685,420 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the commercialization readiness of immune mediator-based blood tests that inform concurrent and future clinical disease activity in systemic lupus erythematosus (SLE). The award aims to validate the Lupus Flare Risk Index (L-FRI) to predict disease flares in SLE patients, and the Lupus Disease Activity Index...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774 to the University of Alabama at Birmingham (UAB) to conduct research on the role of the aryl hydrocarbon receptor (AhR) pathway in suppressing T-bet+ B cells in systemic lupus erythematosus (SLE). The key objectives are to: 1) determine if AhR is required to inhibit the development of T-bet+ B cells in mice...
This Project Grant award in the amount of $405,350 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award will fund research by The Feinstein Institutes for Medical Research to characterize the role of lipid droplets in macrophage function and their consequences in systemic lupus erythematosus (SLE). The research aims to (1) characterize lipid droplets in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $793,093 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Oklahoma Medical Research Foundation to conduct research on systemic lupus erythematosus (SLE) and its cardiovascular disease (CVD) comorbidities. The project aims to systematically study the regulatory effects of genetic variants associated with SLE on macrophage biology, with the goal of identifying dysfunctions, regulatory elements,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $235,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rutgers, The State University of New Jersey. The project aims to develop a novel trispecific killer cell engager (TRIKE) that can efficiently activate natural killer (NK) cells to effectively eliminate pathogenic immune cells in patients with systemic lupus erythematosus (SLE). The research will rigorously evaluate the...